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speciﬁc markers, e.g. growth hormone (GH) and insulin-like
growth factor (IGF-I)] and to compare the results of the 22-item
[8 physical and 14 psychological] Acromegaly Quality-of-Life
questionnaire [ACROQOL] and Short Form-36 Health Survey
[SF-36] in this population. Some of data collected will support
also the ongoing validation of ACROQOL questionnaire.
METHODS: This is the largest European multinational, open,
non-comparative, single evaluation, observational trial evaluat-
ing the HRQOL of patients with acromegaly treated with San-
dostatin® LAR®. This preliminary analysis presents interim
results from 208 Italian and 71 Spanish patients. Recruitment is
ongoing in England, France, Germany, Greece, Portugal, and
Turkey. A total of more than 500 patients are expected. GH and
IGF-I levels were measured within two months of completion 
of the questionnaires and sociodemographic data were also
recorded. Multivariate analyses were used to explore relation-
ship between HRQOL score and clinical and sociodemographic
variables. RESULTS: From this preliminary analysis, there was
no apparent relationship between HRQOL and sociodemo-
graphic variables; and no correlation with levels of GH or IGF-
I. There was a marked correlation between ACROQOL and
physical component score of SF-36, but less signiﬁcant correla-
tion between ACROQOL and mental component score. The
overall impact of acromegaly on HRQOL in patients treated
with Sandostatin® LAR® has not yet been analysed. CON-
CLUSIONS: ACROQOL may be a more descriptive measure of
HRQOL in the acromegaly population than the SF-36. In terms
of the SF-36, there was a superior correlation between the phys-
ical function component and ACROQOL than with the mental
component score, suggesting that the ACROQOL is more sensi-
tive to the psychological impact of the disease.
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OBJECTIVES: To investigate whether long-term GH replace-
ment in GH deﬁcient adults results in improvements in PRO and
HCU in comparison with Dutch population data. METHODS:
Analyses were performed using data from KIMS (Pﬁzer Interna-
tional Metabolic Database). Data were available for 164 Dutch
patients (78 men) for the ﬁrst year of treatment, whereas 2 and
3-year follow-up data were available for 107 and 62 patients
respectively. Quality of life (QoL) was assessed using the Not-
tingham Health Proﬁle (NHP) and disease-speciﬁc QoL-AGHDA
questionnaire. HCU data were obtained with the Patient Life 
Situation Form (PLSF). Statistical analyses were performed with
repeated measurements technique (all values presented as mean
± SEM or mean (95% CI). Normative data for the QoL-AGHDA
questionnaire are currently being collected and will be compared
with patient data. RESULTS: Both QoL measures showed a sig-
niﬁcant sustained improvement over the 3-year treatment period
(from 7.5 ± 0.55 to 5.0 ± 0.59 for NHP, from 10 ± 0.5 to 6.8 ±
0.7 for AGHDA). Data collected with the PLSF showed a sus-
tained subjective improvement in personal well-being for more
than two-third of patients. There was a signiﬁcant decrease from
the previous years in the number of visits to the doctor (from
7.1 (5.7–8.8) to 2.7 (1.7–4.3)), days in hospital (from 5.1
(3.0–8.6) to 1.7 (0.3–8.6)) and days of sick leave (from 39
(0–120) to 1.9 (0–10)) during GH therapy. These data in com-
parison with the average number of visits to the doctor in
2004–5.3 (Source, CBS, 2005), the average number of hospital
days in 2003–4.6 days (Source, Prismant, 2005) and average
number of sick days in 2003 for the Dutch working population—
14.7 (Source, CBS, 2005) showed normalization of HCU CON-
CLUSION: Data obtained conﬁrm that GH replacement therapy
results in a sustained long-term improvement in PRO and nor-
malization of HCU in The Netherlands.
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OBJECTIVES: To evaluate the timing and degree of symptom
relief with rabeprazole in a real life setting of patients with
gastro-oesophageal reﬂux disease (GERD). METHODS: A
prospective, multi-centre, observational study was conducted in
which Canadian general practitioners (n = 115) prescribed
rabeprazole to adults with GERD. Subjects had to be newly diag-
nosed or demonstrate insufﬁcient control on their current PPI,
H2-antagonist and/or antacid and not have used rabeprazole
previously. At the baseline ofﬁce visit (Day 0), physicians col-
lected demographic and clinical history data. Subjects were 
prescribed rabeprazole (2 ¥ 10mg daily) and sent home with a
seven-day diary to record symptom severity and symptom
control. Subjects also completed a Global Symptom Rating on
Day 7 with improvement deﬁned as equal to as or greater than
1 point change in severity rating. RESULTS: Of the 312 subjects
who reported taking rabeprazole on Day 0, more than half were
over 50 years of age and 56% female. The number of subjects
reporting baseline Daytime Heartburn (D-HB), baseline Night-
time Heartburn (N-HB), and Regurgitation (R) were 245, 230
and 194 respectively. 63% of D-HB, 73% of N-HB and 72% of
R reported improvement within the ﬁrst 2 days of therapy. Of
the subjects experiencing improvement during the ﬁrst two days
of therapy, 83% of D-HB, 83% of N-HB and 82% of R main-
tained or further improved symptoms to the end of the study.
Overall, the majority of patients (76%) indicated marked (56%)
or moderate (20%) improvement for the onetime Global
Symptom Rating score on Day 7. CONCLUSIONS: Rabeprazole
demonstrated a high level of effectiveness within the ﬁrst two
days of therapy, which was maintained in subjects with a pro-
longed history of GERD, including those with prior PPI treat-
ment. The results of this real world study provided valuable
information on the true efﬁcacy of rabeprazole.
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OBJECTIVES: To evaluate cost-effectiveness and budget impact
of short and long-term lamivudine antiviral treatment for
chronic hepatitis type B (CHB) in Taiwan. METHODS: A
